WPD Pharmaceuticals Provides Update On Berubicin Drug Candidate in Celebration of National Brain Cancer Day in Canada

Nachrichtenquelle: globenewswire
26.10.2020, 12:30  |  142   |   |   

Presenting at the BIO Europe Digital Conference October 26-29, 2020

VANCOUVER, British Columbia, Oct. 26, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to provide an update on the development of its licensed Berubicin drug candidate in celebration of National Brain Cancer Day on October 24, 2020 in Canada.

WPD is conducting research related to the development of Berubicin, as a novel drug candidate in glioblastoma multiforme (“GBM”) therapy for children and adult patients, as a part of the project “New approach to glioblastoma treatment addressing the critical unmet medical need”. The main goal of the project is to implement a multicenter pediatric phase I clinical trial to determine the maximum tolerated dose and also clinical trials in adults, in order to confirm the efficacy of Berubicin. Berubicin is an innovative drug candidate, licensed from CNS Pharmaceuticals, Inc. in certain territories, being studied to determine its effects on brain cancer cells that are resistant to temozolomide, which today is used as the standard chemotherapeutic. The project also provides for preclinical testing to determine the possible use of Berubicin in combination with temozolomide and with other compounds being developed by WPD and by other companies as candidates for anticancer drugs.

Last week, WPD met with Worldwide Clinical Trials, a world-renowned Contract Research Organization engaged to coordinate and supervise the start-up of WPD’s Phase 1 and 2 clinical trials on Berubicin. The discussions indicated that the Berubicin adult trial is expected to commence in February 2021 and the children multicenter pediatric phase I clinical trial later in 2021. About 60% of the program budget is expected to be refunded by a grant already awarded to WPD by The National Center for Research and Development based in Poland under the European Union’s Smart Growth Operational Program.

BIO Europe Digital Conference

WPD is also pleased to announce that the Company has been invited to present at the Bio-Europe Digital conference October 26-29, 2020. BIO Europe is a leading European Pharmaceuticals event with 4,000 executives from over 60 countries. Due to COVID-19, The BIO Europe conference will be virtual this year and attendees will have access to on demand panels on BD&L, Finance, Therapeutic Areas and up-to-the-minute spotlight topics. For more information on the conference, visit: https://informaconnect.com/bioeurope/.

Seite 1 von 3


WPD Pharmaceuticals Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de

Diesen Artikel teilen


0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

WPD Pharmaceuticals Provides Update On Berubicin Drug Candidate in Celebration of National Brain Cancer Day in Canada Presenting at the BIO Europe Digital Conference October 26-29, 2020VANCOUVER, British Columbia, Oct. 26, 2020 (GLOBE NEWSWIRE) - WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is …

Nachrichten des Autors

Titel
Titel
Titel
Titel